1.
Kardiologiia
; 51(11): 38-44, 2011.
Article
in Russian
| MEDLINE
| ID: mdl-22117769
ABSTRACT
We gave perindopril (10 mg/day) for 24 weeks to 30 patients with arterial hypertension and obesity and proved its ability to effectively lower arterial pressure, exert cardio-, angio-, and nephro-protection, improve parameters of lipid, carbohydrate and purine metabolisms in these patients. Moreover perindopril in these patients diminished manifestations of insulin resistance, hyperleptinemia, and inflammation; it also exerted pronounced positive effect on anthropometric parameters and percent of fat deposits. Basing on the aggregate of clinical and pharmacodynamics effects perindopril can be considered the drug of choice for treatment of arterial hypertension at the background of obesity.
Subject(s)
Blood Pressure/drug effects , Drug Monitoring/methods , Enalapril , Hypertension/drug therapy , Obesity/drug therapy , Perindopril , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Adult , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics , Body Mass Index , Enalapril/administration & dosage , Enalapril/adverse effects , Enalapril/pharmacokinetics , Female , Heart Function Tests , Humans , Hypertension/complications , Hypertension/metabolism , Hypertension/physiopathology , Insulin Resistance , Kidney Function Tests , Male , Metabolism/drug effects , Middle Aged , Obesity/complications , Obesity/metabolism , Obesity/physiopathology , Perindopril/administration & dosage , Perindopril/adverse effects , Perindopril/pharmacokinetics , Protective Agents/administration & dosage , Protective Agents/adverse effects , Protective Agents/pharmacokinetics , Therapeutic Equivalency , Treatment Outcome
2.
Kardiologiia
; 51(9): 22-8, 2011.
Article
in Russian
| MEDLINE
| ID: mdl-22141186